Publication

Article

CURE

Fall 2007
Volume6
Issue 5

Diagnosis Delay

Delayed diagnosis too common.

Experts stress the importance of catching cancer early at its most treatable stage. But in the childhood population, cancer is usually so rare that it’s often overlooked when a child initially has symptoms. The delay in diagnosis can be costly since most childhood cancers are considered fast-growing.

Researchers examined 23 studies conducted between 1976 and 2006 to find any underlying patterns that may contribute to delayed diagnosis, which included the time it took parents to take the child to a physician after symptoms appeared, and from the first health care visit to cancer diagnosis.

Findings of the study, published in August in the journal Cancer, found physician delays to be longer than parent delays in the majority of studies. Factors influencing time to diagnosis included the child’s age, parents’ education level, symptoms, cancer stage, the initial medical specialty consulted, and most significantly, the type of cancer. How those factors relate to prognosis and outcome remains unknown.

The analysis, concluded the authors, is the first step in developing new strategies and programs to shor ten the delay in diagnosis for childhood cancer patients.

Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Related Content